Drug
Beclabuvir clinical trials
Also written BMS-791325.
- studies test it
- 18
- open now
- 0
- in phase 3
- 2
- first study started
- 2008
How studies write it
Studies that test it under each name
Development codes
Combined with it in one product
Studies by the year they started
18 studies that test it; most in 2014 (14)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2010 | 1 |
| 2013 | 2 |
| 2014 | 14 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 12
- Phase 2
- 4
- Phase 3
- 2
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 16 · Other 2
Bristol-Myers Squibb (16) · National Institutes of Health Clinical Center (CC) (1) · Timothy Morgan, MD (1)
Often tested with
Tested in the same studies.
Daclatasvir (9) · Asunaprevir (9) · Ribavirin (2) · Sofosbuvir (1) · Rosuvastatin (1) · Methadone (1) · Buprenorphine (1) · Naloxone (1)
Studies
Open first, then newest update. How each study uses beclabuvir is read from its arms, and is right about nine times in ten.
Testing it · 18
- A Phase 3 Study of a Daclatasvir/Asunaprevir/BMS-791325 Fixed Dose Combination (FDC) in Subjects With Chronic Hepatitis C Genotype 1CompletedPhase 3Bristol-Myers SquibbNCT02170727Written as DCV/ASV/BMS-791325
- Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)CompletedPhase 2Bristol-Myers SquibbNCT02175966Written as DCV/ASV/BMS-791325
- Safety, Tolerability, and Efficacy of Asunaprevir and Daclatasvir in Subjects Coinfected With HIV-HCVCompletedPhase 2National Institutes of Health Clinical Center (CC)NCT02124044Written as Asunaprevir and Daclatasvir with BMS-791325
- Rapid Hepatitis C Elimination Trial- A Pilot Study of Daclatasvir/Asunaprevir/BMS-791325 With or Without Ribavirin To Treat Hepatitis C VirusCompletedNot applicableTimothy Morgan, MDNCT02098616Written as DCV/ASV/BMS-791325
- UNITY 1: A Study of an Investigational Treatment Regimen of Daclatasvir (DCV) + Asunaprevir (ASV) + BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) for 12 Weeks for the Treatment of Chronic Hepatitis C Virus (HCV) Genotype 1 Infection in Non-cirrhotic SubjectsCompletedPhase 3Bristol-Myers SquibbNCT01979939Written as DCV/ASV/BMS-791325
- A Single Ascending Dose Study of BMS-791325 in HCV Infected SubjectsCompletedPhase 1/2Bristol-Myers SquibbNCT00664625Written as BMS-791325
- Ph IIA Study (SOC +/- NS5B)CompletedPhase 2Bristol-Myers SquibbNCT01193361Written as BMS-791325
- Study of Drug Combination on Pharmacokinetics in Healthy VolunteersCompletedPhase 1Bristol-Myers SquibbNCT02175602Written as DCV 3DAA FDC
- Food Effect of a Fixed Dose Combination of Daclatasvir, Asunaprevir and BMS-791325CompletedPhase 1Bristol-Myers SquibbNCT02095860Written as DCV 3DAA FDC
- Drug Interaction Study of an OCP (Norethindrone (ND) Acetate and Ethinyl Estradiol (EE))With a Combination of Daclatasvir (DCV) Asunaprevir (ASV) and BMS-791325CompletedPhase 1Bristol-Myers SquibbNCT02103569Written as BMS-791325
- Study to Determine the Effect of BMS-791325 on the ECG QTcF Interval in Healthy SubjectsCompletedPhase 1Bristol-Myers SquibbNCT02084953Written as BMS-791325
- Drug Interaction Between Daclatasvir/Asunaprevir/BMS-791325 and RosuvastatinCompletedPhase 1Bristol-Myers SquibbNCT02104843Written as Daclatasvir, Asunaprevir and BMS-791325 FDC
- To Assess the Effect of Renal Impairment on the Blood Levels of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325 After Multiple Doses of a Fixed Dose Combination TabletCompletedPhase 1Bristol-Myers SquibbNCT02108639Written as DCV 3DAA FDC
- Absolute Bioavailability of BMS-791325CompletedPhase 1Bristol-Myers SquibbNCT02112110Written as BMS-791325
- Study to Determine the Potential DDIs When the Daclatasvir/Asunaprevir/BMS-791325 Three Drug Antiviral Combination Tablet (FDC) is Coadministered With a Cocktail of Cytochrome P450 (CYP) Probe Substrates and Transporter Probe Substrates (Digoxin and Pravastatin) in Healthy SubjectsCompletedPhase 1Bristol-Myers SquibbNCT02045966Written as DCV 3DAA FDC
- Drug Interaction & Methadone & BuprenorphineCompletedPhase 1Bristol-Myers SquibbNCT02045693Written as DCV 3DAA FDC
- Study to Assess the Effect of BMS-791325 on the Pharmacokinetics of Midazolam in Healthy SubjectsCompletedPhase 1Bristol-Myers SquibbNCT00996879Written as BMS-791325
- Japanese Bridging Study Conducted in the United StatesWithdrawnPhase 1Bristol-Myers SquibbNCT00947245Written as BMS-791325
Given in every arm · 2 — beclabuvir is usual care beside what is tested
- Study to Determine the Effectiveness and Safety of a Three Drug Antiviral Combination Therapy to Treat Hepatitis C Virus (HCV) Infected Patients Not Previously Treated With Currently Available MedicationsCompletedPhase 2Bristol-Myers SquibbNCT01455090Written as BMS-791325
- UNITY 2: A Study of an Investigational Treatment Regimen of DCV+ASV+BMS-791325 in a Fixed Dose Combination (the DCV 3DAA (Direct Acting Antiviral) Regimen) With or Without RBV for 12 Weeks for the Treatment of Chronic Hepatitis C Virus(HCV)Genotype 1 Infection in Subjects With Compensated CirrhosisCompletedPhase 3Bristol-Myers SquibbNCT01973049Written as BMS-791325
Codes
What other systems call beclabuvir · ClinicalTrials.gg INT006453
- UNII (FDA) MYW1X5CO9SBECLABUVIRConfirmed FDA, Wikidata
- Wikidata Q19596032beclabuvirConfirmed FDA, Wikidata
- NCI Thesaurus C114983BeclabuvirOne source FDA
- DrugBank DB12225One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | MYW1X5CO9S | BECLABUVIR | Confirmed FDA, Wikidata |
| Wikidata | Q19596032 | beclabuvir | Confirmed FDA, Wikidata |
| NCI Thesaurus | C114983 | Beclabuvir | One source FDA |
| DrugBank | DB12225 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.